Form 4: PTC Therapeutics SVP, Chief Accounting Officer, Christine Marie Utter, Reports Stock Sales to Cover Tax Obligations

Christine Marie Utter, SVP, Chief Accounting Officer of PTC Therapeutics, reports selling shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• On February 19, 2025, Christine Marie Utter, SVP, Chief Accounting Officer of PTC Therapeutics, sold 879 shares of common stock at a price of $50.096 per share.
• On February 20, 2025, Utter sold 878 shares of common stock at a price of $50.124 per share.
• These sales were executed to cover tax withholding obligations associated with the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and the vesting of 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs.
• Following these transactions, Utter beneficially owns 62,564 shares of PTC Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine stock sales to cover tax obligations, which is a common practice and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sales may have a minor dilutive effect on existing shareholders, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

PTC Therapeutics, Christine Marie Utter, Form 4, Stock Sale, RSU Vesting, Tax Obligations, Beneficial Ownership, Insider Trading